Cargando…

Knockdown of circ_NEK6 Decreased (131)I Resistance of Differentiated Thyroid Carcinoma via Regulating miR-370-3p/MYH9 Axis

Radioresistance is a crucial factor for the failure of iodine 131 ((131)I)-based radiotherapy for differentiated thyroid carcinoma (DTC). This study aimed to explore the effect of circ_NEK6 on the development of (131)I resistance in DTC and its potential mechanism. In this study, we demonstrated tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Fukun, Yin, Shuting, Feng, Zhiping, Liu, Chao, Lv, Juan, Chen, Yuanjiao, Shen, Ruoxia, Wang, Jiaping, Deng, Zhiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093613/
https://www.ncbi.nlm.nih.gov/pubmed/33759638
http://dx.doi.org/10.1177/15330338211004950
Descripción
Sumario:Radioresistance is a crucial factor for the failure of iodine 131 ((131)I)-based radiotherapy for differentiated thyroid carcinoma (DTC). This study aimed to explore the effect of circ_NEK6 on the development of (131)I resistance in DTC and its potential mechanism. In this study, we demonstrated that circ_NEK6 expression was significantly elevated in (131)I-resistant DTC tissues and cell lines. Knockdown of circ_NEK6 significantly repressed (131)I resistance via inhibiting cell proliferation, migration, invasion abilities, and inducing cell apoptosis and DNA damage in (131)I-resistant DTC cells. Mechanistically, knockdown of circ_NEK6 suppressed (131)I resistance in DTC by upregulating the inhibitory effect of miR-370-3p on the expression of myosin heavy chain 9 (MYH9). In vivo experiments showed that circ_NEK6 inhibition aggravated (131)I radiation-induced inhibition of xenograft tumor growth. Taken together, knockdown of circ_NEK6 repressed (131)I resistance in DTC cells by regulating the miR-370-3p/MYH9 axis, indicating that circ_NEK6 may act as a potential biomarker and therapeutic target for DTC patients with (131)I resistance.